SOHO 2023 | The role of ibrutinib in CLL and important adverse events to consider with the use of this agent
Alessandra Ferrajoli
• 7 Sep 2023
Alessandra Ferrajoli, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the role of the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL), and further comments on long-term adverse events (AEs) to consider with the use of this agent. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
